Publications

Google Scholar site: http://scholar.google.com/citations?user=oABj1aUAAAAJ&hl=en

Research Gate site: https://www.researchgate.net/profile/Benyi_Li

Publication in recent 5 years:

  1. Aijing Sun, Changlin Li, Ruibao Chen, Yiling Huang, Qi Chen, Xiangjun Cui, Huafeng Liu, J. Brantley Thrasher and Li B. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. The Prostate, Oct 2015. doi: 10.1002/pros.23106. [Epub ahead of print]. PMID: 26440826 (As corresponding author).

  2. Li B, J. Brantley Thrasher and Paul Terranova. Glycogen Synthase Kinase-3: A Potential Preventive Target for Prostate Cancer. Urol Oncol, 2015 Jun 4. pii: S1078-1439(15)00229-X. PMID: 26051358 (As corresponding author).

  3. Ruibao Chen, Yunqi Zhao, Yan Huang, Qiuhong Yang, Xing Zeng, Wencong Jiang, Jihong Liu, J. Brantley Thrasher, M. Laird Forrest and Li B. Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice. The Prostate 2015 Jan 25. 75(6):593-602. PMID: 25620467. (As corresponding author).

  4. Liu WJ, Xu BH, Ye L, Liang D, Wu HL, Zheng YY, Deng JK, Li B, Liu HF. Urinary proteins induce lysosomal membrane permeabilization and lysosomal dysfunction in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2015 Jan 13:ajprenal.00383.2014. doi: 10.1152/ajprenal.00383.2014. PMID: 25587119.

  5. Li B, Sun A, Jiang W, Thrasher JB, Terranova. PI-3 kinase p110b: a therapeutic target in advanced prostate cancer. Am J Clin Exp Urol 2014, 2(3)188-198. PMID: 25374921 (As corresponding author).

  6. Chunjing Liu, Li B and Lester Mitscher. Synthesis of New TGX-221 Analogs. Naturforsch. 2014, 69b, 817–822. doi:10.5560/ZNB.2014-4081.

  7. Tang Y, Chen R, Huang Y, Li G, Huang Y, Chen J, Duan L, Zhu BT, Thrasher JB, Zhang X, Li B. Natural compound Alternol induces oxidative stress-dependent apoptotic cell death preferentially in prostate cancer cells. Mol Cancer Ther. 2014 Jun; 13(6):1526-36. PMID: 24688053. (As corresponding author).

  8. Liu WJ, Luo MN, Tan J, Chen W, Huang LZ, Yang C, Pan Q, Li B, Liu HF. Autophagy activation reduces renal tubular injury induced by urinary proteins. Autophagy. 2014; 10(2):243-56. doi: 10.4161/auto.27004. PMID: 24345797.

  9. Luo HQ, Kuang XX, Li B. Updated roles of adrenergic receptors in prostate cancer. Zhonghua Nan Ke Xue. 2014 Apr; 20(4):372-6. Review. Chinese. PMID: 24873168. (As corresponding author).

  10. Yao K, Gao XY, Huang BJ, Li ZS, Zhou FJ, Li BY, Han H. Both CK2 catalytic subunits involves in androgen receptor signaling in prostate cancer cells. Zhonghua Yi Xue Za Zhi. 2013 Nov 12; 93(42):3360-3. Chinese. PMID: 24418032

  11. Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, Liu J, Tawfik O, Brantley Thrasher J, Li B. Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol. 2013: S1078-1439(13)00243-3. PMID: 24054868. (As corresponding author).

  12. Yang J, Xie SX, Huang Y, Ling M, Liu J, Ran Y, Wang Y, Thrasher JB, Berkland C, Li B. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor 1 silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond). 2012 Sep; 7(9):1297-309. PMID: 22583574. (As corresponding author).

  13. Zhao Y, Duan S, Zeng X, Liu C, Davies NM, Li B, Forrest ML. Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm. 2012 Jun 4; 9(6):1705-16. Epub 2012 May 1. PMID:22494444.

  14. Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. The Prostate. 2012 Sep 15; 72(13):1423-30. PMID: 22290244.

  15. Cai Z, Li B, Li K, Zhao B. Down-Regulation of Amyloid-β Through AMPK Activation by Inhibitors of GSK-3β in SH-SY5Y and SH-SY5Y-AβPP695 Cells. J Alzheimers Dis. 2012; 29(1):89-98. PMID: 22214783.

  16. Yu J, Chalmers B, Drisko J, Yang J, Li B, Chen Q. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs. 2011 23(4):437-44. PMID:22205155.

  17. Tai W, Shukla RS, Qin B, Li B, Cheng K. Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics, 2011 Jun 6; 8(3):901-12. PMID: 21510670.

  18. Liu J, Youn H, Yang J, Du N, Liu J, Liu H, Li B. G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells. The Prostate, 2011 Sep; 71(12):1276-86. PMID21308712. (As corresponding author).

  19. Zhu Q, Yang J, Han S, Liu J, Holzberlien J, Thrasher JB and Li B. Suppression of GSK-3 activity reduce tumor growth of prostate cancer in vivo. The Prostate, 2011 Jun 1; 71(8):835-45. PMID: 21031441. (As corresponding author).

Last modified: Jan 29, 2016
ID=x7279